New hope for PNH patients: experimental drug HS-10542 enters Mid-Stage trial
Disease control
Recruiting now
This study tests a new drug, HS-10542, in adults with paroxysmal nocturnal hemoglobinuria (PNH) who still have signs of active red blood cell destruction despite current treatments. About 50 participants will receive the drug to see if it safely raises hemoglobin levels and reduc…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 09:16 UTC